TD Asset Management Inc Has $2.09 Million Stock Position in Bicara Therapeutics Inc. $BCAX

TD Asset Management Inc raised its stake in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) by 71.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 224,538 shares of the company’s stock after purchasing an additional 93,600 shares during the quarter. TD Asset Management Inc’s holdings in Bicara Therapeutics were worth $2,086,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of BCAX. GAMMA Investing LLC raised its stake in shares of Bicara Therapeutics by 13,040.7% in the first quarter. GAMMA Investing LLC now owns 7,753 shares of the company’s stock valued at $101,000 after acquiring an additional 7,694 shares during the last quarter. Rhumbline Advisers raised its stake in shares of Bicara Therapeutics by 21.1% in the first quarter. Rhumbline Advisers now owns 23,018 shares of the company’s stock valued at $300,000 after acquiring an additional 4,010 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Bicara Therapeutics by 4.8% in the first quarter. Bank of New York Mellon Corp now owns 42,192 shares of the company’s stock valued at $550,000 after acquiring an additional 1,924 shares during the last quarter. New York State Common Retirement Fund bought a new position in shares of Bicara Therapeutics in the first quarter valued at approximately $52,000. Finally, CWM LLC bought a new position in shares of Bicara Therapeutics in the first quarter valued at approximately $29,000.

Bicara Therapeutics Price Performance

BCAX stock opened at $17.06 on Wednesday. The company has a 50 day moving average price of $13.53 and a 200 day moving average price of $12.11. Bicara Therapeutics Inc. has a fifty-two week low of $7.80 and a fifty-two week high of $28.09. The stock has a market capitalization of $931.65 million and a PE ratio of -5.38.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.04. As a group, equities analysts expect that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current fiscal year.

Insider Activity at Bicara Therapeutics

In other Bicara Therapeutics news, CEO Claire Mazumdar sold 13,289 shares of Bicara Therapeutics stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $18.84, for a total transaction of $250,364.76. Following the completion of the sale, the chief executive officer owned 309,892 shares of the company’s stock, valued at approximately $5,838,365.28. The trade was a 4.11% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider David Raben sold 22,000 shares of Bicara Therapeutics stock in a transaction on Thursday, October 9th. The stock was sold at an average price of $18.45, for a total transaction of $405,900.00. Following the sale, the insider directly owned 35,497 shares of the company’s stock, valued at $654,919.65. This represents a 38.26% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 146,534 shares of company stock worth $2,682,012.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on BCAX. Wedbush reiterated an “outperform” rating and issued a $30.00 target price on shares of Bicara Therapeutics in a research note on Tuesday, August 12th. Piper Sandler began coverage on shares of Bicara Therapeutics in a research note on Monday, August 18th. They issued an “overweight” rating and a $36.00 target price for the company. HC Wainwright cut their target price on shares of Bicara Therapeutics from $41.00 to $40.00 and set a “buy” rating for the company in a research note on Friday, August 22nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Bicara Therapeutics in a research note on Tuesday, October 14th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $31.86.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.